Cenyx Biotech

Cenyx Biotech is a South Korean nanomedicine company developing first-in-class nanozyme therapeutics for acute and chronic inflammatory and neurological diseases. The company's proprietary cerium oxide-based nanozyme platform mimics enzyme activity to neutralize reactive oxygen species, with four pipeline candidates including CX213 for subarachnoid hemorrhage and acute liver failure, which received FDA IND clearance for a Phase 1 trial in 2024. Cenyx Biotech positions itself as a pioneering company bringing the first nanozyme-based drug into human clinical trials.